Dr. Rini Describes Axitinib's and Sorafenib's Side Effects

Winship Grand Rounds July 19, 2017: Mehmet Asim Bilen, MDПодробнее

Dr. Rini on the Axitinib and Sorafenib Trial Hazard RatioПодробнее

Dr. Rini on the Results From His Axitinib and Sorafenib TrialПодробнее

Dr. Rini Explains the Axitinib Integration ProcessПодробнее

Dr. Rini on the Axitinib and Sorafenib Trial VEGF FocusПодробнее

Axitinib Showed Two-Month Advantage To SorafenibПодробнее

Dr. Rini Describes Hypertension as a Biomarker in RCCПодробнее

Dr. Rini on Standards of Care for Advanced RCCПодробнее

Dr. Rini Describes Axitinib's and Sorafenib's Side EffectsПодробнее

Dr. Rini Discusses the VEGF Targeted Agent AxitinibПодробнее

AGILE Trial: Frontline Axitinib Versus Sorafenib in Metastatic Renal Cell CarcinomaПодробнее

Dr. Nicholas Vogelzang on First-Line Axitinib Versus Sorafenib in mRCCПодробнее

Dr. Cella Discusses Axitinib and Sorafenib Axis TrialПодробнее

Dr. Rini on the Progression of Advanced RCC TherapyПодробнее

Dr. Cella on the Side Effect Focus of the Axitinib and Sorafenib TrialПодробнее

Phase 3 AXIS 1032 Trial Discussion with Brian I. Rini, MDПодробнее

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaПодробнее

AXIS Trial: Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell CarcinomaПодробнее

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCCПодробнее

Dr. Rini on Pembrolizumab Plus Axitinib in RCCПодробнее